Current Research Studies

Research Studies and Clinical Trials

  • The purpose of this study is to evaluate the safety and tolerability of multiple ascending intravenous infusions of BMS-986168 and to assess the pharmacodynamics of BMS-986168 on cerebrospinal fluid (CSF) extracellular tau (eTau) concentrations in patients with progressive supranuclear palsy.

  • This study will evaluate the safety and tolerability (maximum tolerated dose (MTD) within the specified dosing range) of single intravenous (IV) infusion of C2N-8E12 in patients with progressive supranuclear palsy (PSP).

  • This study is to determine the dose of TPI-287 that is safe and tolerable in people with mild to moderate AD, as well as to measure the properties and preliminary efficacy of TPI-287.

  • This is a multi-center, open label, pilot futility clinical trial of the safety, tolerability, pharmacodynamics and preliminary efficacy of oral salsalate in up to 10 patients with PSP.

  • This is a phase 1, multi-center, open-label study of the safety, tolerability, pharmacodynamics, and preliminary efficacy of young (<30 years of age) healthy male donor plasma transfusions in patients with PSP. Up to 10 subjects will receive once monthly 4-unit transfusions of young healthy male donor plasma for 6 months.

  • Search for "progressive supranuclear palsy", "corticobasal degeneration", or "multiple system atrophy".

  • The goal of this study is to identify rare genetic variants as risk factors for progressive supranuclear palsy (PSP). By studying patients with PSP and their relatives affected by related conditions, we hope to identify genes that are involved in PSP and related disorders.

  • This study will evaluate 18F-AV-1451 for brain imaging of tau in subjects with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and healthy volunteers.

  • The purpose of this study is to determine the safety and tolerability (maximum tolerated dose (MTD) within planned dosing range) of intravenous (IV) infusions of TPI-287 administered once every 3 weeks for 9 weeks (for a total of 4 infusions) in patients with primary four repeat tauopathies (4RT), corticobasal syndrome (CBS) or progressive supranuclear palsy (PSP).

  • The hypothesis is that pyridostigmine will improve the safety factor of ganglionic neural transmission, while Droxidopa will replete the postganglionic neuron of norepinephrine (NE). This combination should result in enhanced orthostatic release of NE. The investigators have already demonstrated that pyridostigmine does not raise supine blood pressure.

  • The goal of this study is to identify the best methods of analysis for tracking PSP and CBD over time. The results from this study may be used in the future to calculate power for clinical drug trials, as this study aims to identify the most reliable outcome measures.

DISCLAIMER NOTICE: Publication by CurePSP of these studies is solely for research and scientific advancement purposes only, and their publication by CurePSP is neither an endorsement nor warranty by CurePSP of their results or conclusions.